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Abstract
We developed an automated point-of-care diagnostic instrument that is capable of 
analyzing nasal swab samples for the presence of respiratory diseases.  This robust 
instrument, called FluIDx, performs autonomous multiplexed RT-PCR reactions that are 
analyzed by microsphere xMAP technology. We evaluated the performance of FluIDx,
in comparison rapid tests specific for influenza and respiratory syncytial virus, in a 
clinical study performed at the UC Davis Medical Center.   The clinical study included 
samples positive for RSV (n = 71), influenza A (n = 16), influenza B (n = 4), adenovirus 
(n = 5), parainfluenza virus (n = 2), and 44 negative samples, according to a composite 
reference method.  FluIDx and the rapid tests detected 85.9% and 62.0% of the RSV 
positive samples, respectively.  Similar sensitivities were recorded for the influenza B 
samples; whereas the influenza A samples were poorly detected, likely due to the 
utilization of an influenza A signature that did not accurately match currently circulating 
influenza A strains.  Data for all pathogens were compiled and indicate that FluIDx is 
more sensitive than the rapid tests, detecting 74.2% (95% C.I. of 64.7 - 81.9%) of the 
positive samples in comparison to 53.6% (95% C.I. of 43.7 - 63.2%) for the rapid tests.  
The higher sensitivity of FluIDx was partially offset by a lower specificity, 77.3% versus
100.0%.  Overall, these data suggest automated flow-through PCR-based instruments that 
perform multiplexed assays can successfully screen clinical samples for infectious 
diseases.  
Introduction/Background
This project was funded by the LDRD committee to address the lack of rapid and 
accurate diagnostic tools at our healthcare facilities.  The diagnostic tools currently 
available to point-of-care physicians are limited to immuno-assay based rapid test strips, 
which are only approximately 70% sensitive and screen for only one or two pathogens at 
a time.  RT-PCR assays are approximately 100-fold more sensitive than immuno-assays 
and can be multiplexed to detect many pathogens in one assay.  Currently, RT-PCR 
analysis requires a skilled technician working in a fully equipped clinical microbiology 
laboratory.  The purpose of this LDRD project was to develop an automated instrument 
that would essentially replace the requirement of having a skilled technician perform 
manual RT-PCR assays to diagnosis a patient’s sample.  During the first two years of this 
LDRD project, we developed the first-ever bead-based multiplex instrument that is fully 
automated.  The last year of the LDRD project focused on the evaluation of this new 
instrument against the immuno-assay tests.  The positive data generated during the 
clinical trial demonstrates the proof-of-principle behind automating these types of assays 
and will hopefully lay the groundwork to bringing bead-based multiplex assays out of the 
laboratory and to the point-of-care where they will offer a better diagnostic alternative 
than immuno-assay tests.  The arrival of this type of technology to the clinic will change 
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the manner in which care is delivered, including decisions surrounding prescribing anti-
microbial drugs and admitting or discharging patients.  
Results
Detailed descriptions of both the automated instrument and the clinical study are 
provided in the attached manuscripts, which at the time of writing this report, are being 
submitted for publication to the Journal of Clinical Microbiology.  The first manuscript 
details the construction and operation of the instrument, and an analytical study that 
evaluated the ability of the instrument to reliably analyze samples in a reproducible 
manner.  The second paper details the results of a clinical study using FluIDx and rapid 
tests to diagnose patient samples collected at the UC Davis Medical Center.  The clinical 
study involved screening 141 nasal swab samples for respiratory viruses.  Analysis of 
these data indicates that FluIDx is more sensitive, but less specific than the rapid tests.  
FluIDx has the added advantage of being able to screen for multiple pathogens at a time, 
thereby reducing overall cost and labor associated with determining the diagnosis of a 
sample.  
Exit Plan
LLNL’s Industrial Partnership Office has licensed FluIDx intellectual property to 
Tassajara Technologies and is currently negotiating a CRADA agreement to facilitate the 
commercialization of this technology in the private sector.
